Peptide library
The compounds people ask about most. Each entry shows the legal lane and how people access it. Select a name for the full page, with an evidence grade and reported dosing. If you would rather start from what you are trying to do, use the finder.
FDA-approved
| Compound | What it is | How it is accessed |
|---|---|---|
| Semaglutide Approved | A GLP-1 medication sold as Wegovy and Ozempic. Available as a weekly injection and, since January 2026, a daily Wegovy pill. | Prescription, filled by any pharmacy or through the manufacturer's self-pay program. |
| Tirzepatide Approved | A medication that acts on two hormone receptors, GIP and GLP-1. Sold as Zepbound and Mounjaro. Weekly injection. | Prescription, filled by any pharmacy or through the manufacturer's self-pay program. |
| Tesamorelin Approved | A daily injection that prompts growth hormone release. Sold as Egrifta. | Prescription. Approved only to reduce excess abdominal fat in people with HIV and lipodystrophy. |
Long-standing compounded prescriptions
| Compound | What it is | How it is accessed |
|---|---|---|
| Sermorelin Compounded | A peptide that signals the body to release growth hormone. Not currently sold as an FDA-approved product. | Prescription, compounded by a licensed pharmacy. |
| NAD+ Compounded | A coenzyme involved in cell metabolism. Not a peptide, but sold alongside them. | Prescription, compounded by a licensed pharmacy. |
Newly permitted under the October 2026 policy
These six are covered by an interim HHS policy. None is FDA-approved. The policy lists the specific form and route for each, shown below.
| Compound | What it is | Form and route covered |
|---|---|---|
| BPC-157 Interim policy | A synthetic 15-amino-acid peptide. Studied mostly in animals, with very limited human trial data. | BPC-157 acetate: injection under the skin or into muscle, oral, or topical. |
| TB-500 Interim policy | A synthetic peptide related to thymosin beta-4. Often paired with BPC-157. | TB-500 acetate: injection under the skin or into muscle. |
| KPV Interim policy | A three-amino-acid peptide (lysine, proline, valine). | KPV acetate: oral and topical. |
| MOTS-c Interim policy | A peptide encoded in mitochondrial DNA. | MOTS-c acetate: injection under the skin or into muscle. |
| Semax Interim policy | A synthetic peptide given as a nasal spray. | Semax free base: intranasal only. |
| Epitalon Interim policy | A synthetic four-amino-acid peptide. | Epitalon acetate: injection under the skin or into muscle, in intermittent courses. |
On the evidence: FDA scientists reviewed these six, plus one more, in July 2026 and recommended against all seven. An advisory committee voted to recommend six anyway. Sellers promote them for healing, inflammation, metabolism and longevity; those uses have not been established in human trials.
Approved hormones often sold alongside peptides
| Compound | What it is | How it is accessed |
|---|---|---|
| Growth hormone (HGH) Approved | Somatropin, a copy of the body's own growth hormone. Approved for deficiency and specific conditions. | Prescription for approved uses only. Federal law bars distribution for anti-aging or bodybuilding. |
| HCG Approved | A hormone that imitates the body's signal to ovulate or to make testosterone. | Prescription. Approved for fertility and certain cases of low testosterone, not for weight loss. |
Not legally available in the US
These have no approved product and no lawful compounding route. Anything sold under these names is unapproved and unverified.
| Compound | What it is | How it is accessed |
|---|---|---|
| Retatrutide Investigational | Eli Lilly's experimental triple-hormone weight-loss injection, with strong Phase 3 results. | Clinical trials only. An FDA filing is planned for early 2027. |
| Mazdutide Not approved in US | A weekly weight-loss injection approved in China in 2025. | Not available in the US. |
| Melanotan II Gray market | A tanning and libido peptide with melanoma and mole reports. | No legal route. FDA review due by February 2027. |
| GHK-Cu and the Glow stack Awaiting review | A copper peptide common in skincare, also sold as an injection and in the Glow blend. | Topical: sold as a cosmetic. Injectable: not approved, FDA review due by February 2027. |
| Ipamorelin Not approved | A growth hormone secretagogue, usually sold paired with CJC-1295. Its one Phase 2 trial, in post-surgical recovery, failed. | No lawful compounding route. An advisory committee voted 0 to 12 against adding it. |
| CJC-1295 Not approved | A long-acting growth-hormone-releasing peptide. Human data is a 2006 Phase 1 program measuring hormone levels only. | No lawful compounding route. Development was halted. |
| GHRP-2 and GHRP-6 Research chemical | Older growth hormone releasers that also raise cortisol, prolactin and appetite. GHRP-2 is approved only in Japan, as a diagnostic. | No US approval or compounding route. Sold as research chemicals. |
| IGF-1 LR3 Research reagent | An engineered IGF-1 analog sold for muscle growth. No human trials. The approved IGF-1 drug carries hypoglycemia and malignancy warnings. | No lawful route. Sold as a laboratory reagent. |
| Selank Not approved in US | An anti-anxiety nasal peptide approved in Russia, with small trials from Russian groups only. | Not available in the US. Nomination withdrawn; not eligible for compounding. |
| DSIP Rejected for compounding | A sleep peptide isolated in 1977. The one compound of seven the advisory committee voted against in July 2026. | No lawful compounding route. |
| Kisspeptin Investigational | A reproductive hormone with real controlled trials in fertility and sexual desire. The form sold online differs from the one studied. | Investigational. No approved product. |
| AOD-9604 Not approved | A growth hormone fragment. Its 536-person obesity trial found no significant weight loss against placebo. | Not FDA-approved. Compounding status has shifted repeatedly; verify before assuming availability. |
| Adipotide Research chemical | A fat-targeting peptide that caused dose-dependent kidney damage in every treated primate. Never completed a human trial. | No lawful route. Development stopped over the toxicity. |
| Dihexa Research chemical | A cognition peptide with no human data and a retracted mechanism paper. FDA review due February 2027. | No lawful route. Sold as a research chemical. |
| SLU-PP-332 Preclinical | The 'exercise pill' ERR agonist. Striking mouse endurance and weight results; no human trials registered. | No lawful route. Preclinical research compound. |
Not peptides, but sold alongside them
| Compound | What it is | How it is accessed |
|---|---|---|
| Methylene blue Approved, one use | A synthetic dye and prescription drug, FDA-approved by injection for methemoglobinemia. Now sold in dropper bottles for focus and energy, with a boxed warning about serotonin syndrome. | Prescription for its approved use. Supplement versions are unregulated and vary in purity. |
| 5-amino-1MQ Research chemical | A small molecule that blocks the NNMT enzyme. Striking mouse fat-loss data; no human trials have been published or registered. | Not FDA-approved. Sold as a research chemical. |
Blends and stacks
Multi-peptide vials sold under names like Wolverine, Glow and KLOW. The October 2026 policy permits its six peptides one at a time; a vial holding several of them falls outside it. What is in each blend, and why that matters.
Comparisons
- Semaglutide vs tirzepatide: the head-to-head trial, pill vs injection, and price.
- BPC-157 vs TB-500: how the two repair peptides differ.
What is next
An FDA advisory committee is scheduled to review five more compounds in February 2027: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and PEG-MGF. We will add them as their status becomes clear.
Sources
- GoodRx: FDA developments on peptides (forms and routes covered by the policy; advisory committee votes)
- National Law Review: HHS policy on peptide compounding
- Center for Science in the Public Interest: statement on the advisory committee vote